ATG4B and neoplasm: MiR-93 can suppress autophagic activity by downregulating the expression of BECN1, ATG4B, ATG5, and SQSTM1 in glioblastoma stem cells (GSCs), which results in the suppression of tumor cell growth and glioma sphere self-renewal and the enhancement of temozolomide (TMZ) activity to combat tumor progression by inhibiting autophagy [84].